by The global CRISPR & Cas genes market is valued at USD 3.67 billion in 2024 and is projected to reach USD 17.49 billion by 2034, growing at a CAGR of 16.90%.
CRISPR & Cas Genes Market Key Takeaways
- North America dominated the global market with a 39% share in 2024.
- Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
- The biomedical segment led the market by application in 2024.
- The product segment accounted for the highest revenue share by product & service in 2024.
- The biotechnology and pharmaceutical segment held the largest market share by end-user in 2024.
The CRISPR & Cas genes market is experiencing significant growth, driven by advancements in gene-editing technologies and increasing applications in biotechnology and healthcare. In 2024, the market was valued at USD 3.67 billion and is projected to reach USD 17.49 billion by 2034, growing at a CAGR of 16.90%. North America led the global market with a 39% share, while Asia Pacific is expected to expand at the fastest CAGR during the forecast period.
The biomedical segment held the largest market share by application in 2024, while the product segment generated the highest revenue under product & service. By end-user, the biotechnology and pharmaceutical segment dominated the market, reflecting the growing demand for CRISPR-based solutions in drug discovery, genetic research, and disease treatment.
Sample Link: https://www.precedenceresearch.com/sample/1108
Key Drivers
Opportunities
- Expanding applications of CRISPR in gene therapy, disease treatment, and precision medicine.
- Increasing investment in biotechnology and pharmaceutical R&D.
- Growing demand for genetically modified crops and improved agricultural productivity.
- Advancements in AI and bioinformatics enhancing CRISPR research and applications.
- Rising collaborations between academic institutions, biotech firms, and government bodies.
- Emerging markets in Asia-Pacific offer significant growth potential.
Challenges
- Ethical and regulatory concerns surrounding gene editing and human genome modification.
- Potential off-target effects and unintended genetic mutations.
- High costs associated with CRISPR-based treatments and research.
- Stringent approval processes and complex regulatory frameworks.
- Public perception and ethical debates impacting adoption rates.
- Intellectual property disputes and patent-related challenges in CRISPR technology.
Regional Insights
North America leads the CRISPR & Cas genes market, holding the largest market share due to strong investments in biotechnology, advanced healthcare infrastructure, and supportive government initiatives. The United States is a key contributor, driven by extensive research in gene editing and the presence of major biotech companies. Europe follows closely, with the growing adoption of CRISPR technology in pharmaceutical research and genetic engineering, supported by regulatory advancements.
The Asia Pacific region is expected to witness the fastest growth, fueled by rising investments in biotechnology, increasing demand for precision medicine, and government support for genetic research, particularly in China and Japan. Latin America and the Middle East & Africa are emerging markets, with gradual adoption driven by growing awareness and investment in healthcare and agricultural biotechnology.
Don’t Miss Out: Solid Tumor Cancer Treatment Market
Market Key Players
- Genscrip
- Danaher Corporation
- Lonza
- Merck KGaA
- Synthego
- Mammoth Biosciences
- Inscripta, Inc.
- Cibus
- New England BioLabs
- Takara Bio, Inc.
Recent News
In December 2024, Wired reported on the first clinical use of Casgevy, a groundbreaking CRISPR-based therapy designed to treat sickle cell disease. Despite its approval, the therapy’s rollout has been gradual due to manufacturing challenges, insurance complexities, and the extensive preparation required for patients. Casgevy involves collecting and editing a patient’s stem cells, followed by chemotherapy and hospitalization. While clinical trials have shown promising results, with many patients experiencing significant relief, the therapy’s complexity and high cost of $2.2 million pose challenges for widespread adoption.
In November 2024, The Wall Street Journal reported that Chinese biologists utilized CRISPR technology to create sweeter tomatoes by increasing their glucose and fructose content by 30%. This effort aims to make foods more appealing to consumers. The modified tomatoes are part of broader research to enhance the taste and nutritional value of crops. However, bringing these gene-edited tomatoes to market will require governmental approvals, which may take time.
Additionally, in February 2025, EIN Presswire reported that the CRISPR & Cas genes market is projected to reach USD 22.82 billion by 2034, growing at a CAGR of 16.7%. This growth is driven by increasing funding in gene therapy and expanding applications of CRISPR technology in therapeutic solutions, agriculture, and drug discovery. North America currently leads the market, with significant contributions from the U.S., while the Asia Pacific region is expected to witness the fastest growth due to rising investments in biotechnology and supportive government initiatives.
Market Segmentation
By Product & Service
- By Service
- Microbial Gene Editing
- Cell Line Engineering
- gRNA Design
- DNA Synthesis
- By Product
- Design Tool
- Kits & Enzymes
- Libraries
- Antibodies
- Others
By Application
- Agricultural
- Biomedical
- Functional Genomics
- Genome Engineering
- Disease Model Studies
- Epigenetics
- Others
End-use Outlook
-
- Contract Research Organizations (CROs),
- Academics & Government Research Institutes
- Biotechnology & Pharmaceutical Companies
